WO2004037226B1 - Compositions pharmaceutiques renfermant de la venlafaxine - Google Patents

Compositions pharmaceutiques renfermant de la venlafaxine

Info

Publication number
WO2004037226B1
WO2004037226B1 PCT/IL2003/000862 IL0300862W WO2004037226B1 WO 2004037226 B1 WO2004037226 B1 WO 2004037226B1 IL 0300862 W IL0300862 W IL 0300862W WO 2004037226 B1 WO2004037226 B1 WO 2004037226B1
Authority
WO
WIPO (PCT)
Prior art keywords
core
venlafaxine
outer coating
water
burst
Prior art date
Application number
PCT/IL2003/000862
Other languages
English (en)
Other versions
WO2004037226A3 (fr
WO2004037226A2 (fr
Inventor
Adel Penhasi
Mila Gomberg
Avi Avramoff
Original Assignee
Dexcel Pharma Technologies Ltd
Adel Penhasi
Mila Gomberg
Avi Avramoff
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/280,084 external-priority patent/US6703044B1/en
Application filed by Dexcel Pharma Technologies Ltd, Adel Penhasi, Mila Gomberg, Avi Avramoff filed Critical Dexcel Pharma Technologies Ltd
Priority to US10/532,407 priority Critical patent/US20060057204A1/en
Priority to CA002503380A priority patent/CA2503380A1/fr
Priority to EP03758627A priority patent/EP1558222A2/fr
Priority to AU2003274655A priority patent/AU2003274655A1/en
Publication of WO2004037226A2 publication Critical patent/WO2004037226A2/fr
Publication of WO2004037226A3 publication Critical patent/WO2004037226A3/fr
Publication of WO2004037226B1 publication Critical patent/WO2004037226B1/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/54Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
    • C07C217/74Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with rings other than six-membered aromatic rings being part of the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14The ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne une formulation retard à libération progressive comprenant un noyau présenté sous la forme d'une pastille comprimée et un enrobage externe entourant le noyau renfermant la venlafaxine ou un sel acceptable sur le plan pharmaceutique de celle-ci, au moins un agent de commande de décharge et un désintégrant; l'enrobage externe comprenant un véhicule hydrophobe insoluble dans l'eau et une matière particulaire insoluble dans l'eau mais hydrophile.
PCT/IL2003/000862 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine WO2004037226A2 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/532,407 US20060057204A1 (en) 2002-10-25 2003-10-23 Pharmaceutical compositions containing venlafaxine
CA002503380A CA2503380A1 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine
EP03758627A EP1558222A2 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine
AU2003274655A AU2003274655A1 (en) 2002-10-25 2003-10-23 Pharmaceutical compositions containing venlafaxine

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US10/280,084 US6703044B1 (en) 2002-10-25 2002-10-25 Venlafaxine formulations
US10/280,084 2002-10-25
IL158,493 2003-10-20
IL15849303A IL158493A0 (en) 2002-10-25 2003-10-20 Pharmaceutical compositions containing venlafaxine

Publications (3)

Publication Number Publication Date
WO2004037226A2 WO2004037226A2 (fr) 2004-05-06
WO2004037226A3 WO2004037226A3 (fr) 2004-07-08
WO2004037226B1 true WO2004037226B1 (fr) 2004-09-10

Family

ID=32178938

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2003/000862 WO2004037226A2 (fr) 2002-10-25 2003-10-23 Compositions pharmaceutiques renfermant de la venlafaxine

Country Status (4)

Country Link
EP (1) EP1558222A2 (fr)
AU (1) AU2003274655A1 (fr)
CA (1) CA2503380A1 (fr)
WO (1) WO2004037226A2 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007520547A (ja) * 2004-02-04 2007-07-26 アレムビック・リミテッド ベンラファキシン塩酸塩の徐放性コーティングされた小型錠剤
US20090175934A1 (en) * 2006-03-08 2009-07-09 Jubilant Organosys Ltd. Extended Release Pharmaceutical Formulation of Venlafaxine and Method of Manufacturing the Same
WO2007112574A1 (fr) * 2006-04-03 2007-10-11 Isa Odidi Composition de venlafaxine à libération prolongée
US9381248B2 (en) * 2010-08-31 2016-07-05 Toray Industries, Inc. Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6274171B1 (en) * 1996-03-25 2001-08-14 American Home Products Corporation Extended release formulation of venlafaxine hydrochloride
US6572890B2 (en) * 2000-01-13 2003-06-03 Osmotica Corp. Osmotic device containing venlafaxine and an anti-psychotic agent
EP1474123A1 (fr) * 2002-01-03 2004-11-10 LEK Pharmaceuticals D.D. Formulation pharmaceutique a liberation controlee contenant de la venlafaxine

Also Published As

Publication number Publication date
WO2004037226A3 (fr) 2004-07-08
EP1558222A2 (fr) 2005-08-03
AU2003274655A8 (en) 2004-05-13
AU2003274655A1 (en) 2004-05-13
WO2004037226A2 (fr) 2004-05-06
CA2503380A1 (fr) 2004-05-06

Similar Documents

Publication Publication Date Title
AU2001268722B2 (en) Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
CA2446712C (fr) Systeme d'administration osmotique d'agents pharmaceutiquement actifs
AU733801B2 (en) Multiple unit effervescent dosage form
ES2355099T3 (es) Dispositivo osmótico dentro de un dispositivo osmótico.
KR101834033B1 (ko) 주의력 결핍 장애 치료용 고체 경구 제약 조성물
JP5572616B2 (ja) 口腔内分散性多層錠剤
RU2314810C2 (ru) Способ лечения с использованием лекарственных форм, содержащих фармацевтические композиции 5,8,14-триазатетрацикло[10.3.1.0 (2,11).0(4,9)] гексадека-2( 11),3,5,7,9-пентаена
EP1909770B1 (fr) Composition a liberation orale controlee contenant du levetiracetam
WO2007000778A3 (fr) Compositions pharmaceutiques a liberation modifiee et leurs procedes
IL211075A (en) Multi-component preparation with irregular release
CA2126611A1 (fr) Formulations d'opioides a liberation prolongee
CA2434484A1 (fr) Compositions comprenant de l'ibuprofene et de la diphehydramine destinees a traiter les troubles du sommeil lies a la douleur
AU2002303897A1 (en) System for osmotic delivery of pharmaceutically active agents
CA2628200A1 (fr) Compositions pharmaceutiques solides contenant de la pregabaline
US6080427A (en) Cefadroxil monohydrate tablet formulation
CA2330480A1 (fr) Preparation a liberation controlee de divalproex sodium
SG146638A1 (en) Pharmaceutical delivery system
JP2002530322A5 (fr)
JP2005528430A5 (fr)
NZ514129A (en) Tolperison-containing, pharmaceutical preparation for oral administration
EP1679066A1 (fr) Microparticule enrobee contenant un medicament pour comprime a dissolution orale
WO2004037226B1 (fr) Compositions pharmaceutiques renfermant de la venlafaxine
MXPA04009906A (es) Composiciones farmaceuticas de liberacion controlada de carbipoda y levopoda.
RU2002109236A (ru) Композиции с контрлируемым высвобождением для перорального применения
JPS62142113A (ja) 口腔粘膜付着用錠剤

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
B Later publication of amended claims

Effective date: 20040726

ENP Entry into the national phase

Ref document number: 2006057204

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2503380

Country of ref document: CA

Ref document number: 10532407

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2003758627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2003758627

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10532407

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: JP